Accelerate Diagnostics Enters into Securities Purchase Agreement

Trending News ☀️

Accelerate Diagnostics Stock Intrinsic Value – Accelerate Diagnostics ($NASDAQ:AXDX), Inc. is a molecular diagnostics company that develops and commercializes innovative solutions for identifying infectious pathogens. On March 8, 2019, the company entered into a Securities Purchase Agreement with the investors named therein.

A copy of the agreement is attached as Exhibit 10.1 and is incorporated herein by reference. The proceeds from the sale of the securities will be used to fund the company’s operations and for general corporate purposes.

Share Price

On Tuesday, Accelerate Diagnostics stock opened at $1.5 and closed at $1.6, soaring by 11.9% from the previous closing price of $1.4. The news of the company’s securities purchase agreement has been met with mostly positive coverage. The agreement is a major step forward for the company, and investors are clearly confident in its future prospects. With the added capital, Accelerate Diagnostics will be able to accelerate its growth plans and continue to innovate its products and services.

This is good news for patients and healthcare providers alike, as the company’s technology has the potential to improve diagnosis and treatment of various diseases. The agreement is also a vote of confidence from the investment community in Accelerate Diagnostics’ business model and management team. The company has shown strong execution so far, and with the additional capital it will be well-positioned to continue executing on its growth strategy.

VI Analysis – Accelerate Diagnostics Stock Intrinsic Value

Accelerate Diagnostics, Inc. is a molecular diagnostics company. The Company develops, manufactures and commercializes solutions for the diagnosis of infectious diseases. Its solutions include instruments, software, reagents and controls that are used by laboratories for the diagnosis of serious and often life-threatening infections. The Company’s solutions provide its customers with results from a single patient sample in approximately three hours, including identification of the causative organism and antimicrobial susceptibility results.

These results enable its customers to optimize patient therapy and improve patient outcomes. The Company’s products include Pheno system, Pathfinder and Accelerate PhenoTest BC-GP.

Summary

The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include sales and marketing activities, research and development, and capital expenditures. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.